Autosomal Dominant Hearing Loss 78 (DFNA78, SLC12A2-related) — Comprehensive Disease Report

Prepared as a disease knowledge-base entry. Evidence types are flagged as [human clinical], [model organism], [in vitro], or [computational]. Primary citations are given as PMIDs.

Summary / Consensus Answer

DFNA78 is a rare, autosomal dominant, non-syndromic sensorineural hearing loss (frequently accompanied by bilateral vestibular areflexia) caused by heterozygous variants in SLC12A2, the gene encoding the secretory Na⁺-K⁺-2Cl⁻ cotransporter NKCC1. The pathogenic variants cluster in exon 21 (or its 3′ splice site), a region present almost exclusively in the cochlea-specific NKCC1 isoform that is required to maintain the K⁺-rich endolymph and endocochlear potential that drive hair-cell mechanotransduction. Reduced/dysfunctional cotransport disrupts endolymph homeostasis, leading to hair-cell dysfunction and hearing/vestibular loss. Management is supportive (hearing aids, cochlear implantation, vestibular rehabilitation); no disease-specific pharmacotherapy exists.

1. Disease Information

Overview. DFNA78 ("Deafness, autosomal dominant 78") is a Mendelian sensorineural hearing loss (SNHL) caused by heterozygous SLC12A2 variants. It was first delineated in 2020 [human clinical; 32294086; 32658972]. The phenotype is congenital-to-early-onset, bilateral SNHL, often severe-to-profound, and frequently with bilateral vestibular areflexia (hence sometimes described as a cochleovestibular defect) [PMID 32658972; 40503591].

"In 2020, heterozygous variants in SLC12A2 were identified as a cause of non-syndromic deafness associated with vestibular areflexia (DFNA78; MIM 619081)." — 40503591

Key identifiers (verified via OLS4/MONDO, 2026-09-03). - OMIM: #619081 (Deafness, autosomal dominant 78) - Gene OMIM: SLC12A2 600840 - MONDO: MONDO:0033665 ("hearing loss, autosomal dominant 78") - DOID: DOID:0112159; GARD: 0018156; MedGen: C5436768 (CUI 1777362); UMLS: C5436768 - Orphanet: No dedicated DFNA78 ORPHAcode (MONDO records no Orphanet xref); clinically grouped under autosomal dominant non-syndromic sensorineural hearing loss. - ICD-11: AB52 Sensorineural hearing impairment (bilateral, AB52.0); ICD-10: H90.3/H90.5 - MeSH: "Hearing Loss, Sensorineural" (D006319); "Hearing Loss, Bilateral" - HGNC gene: HGNC:10911 (SLC12A2); NCBI Gene: 6558; Ensembl: ENSG00000064651; UniProt: P55011 (NKCC1)

Synonyms / alternative names: DFNA78; deafness, autosomal dominant 78; SLC12A2-related autosomal dominant deafness; NKCC1-related hearing loss; non-syndromic sensorineural hearing loss with vestibular areflexia. Distinct allelic disorders (same gene, different phenotype/inheritance): Delpire-McNeill syndrome — neurodevelopmental disorder, MONDO:0033667, OMIM #619083, Orphanet:633024 [PMID 32658972]; Kilquist syndrome — autosomal recessive multisystem disorder, MONDO:0033664, OMIM #619080, Orphanet:633021 [PMID 30740830].

Data source type: Aggregated disease-level knowledge derived from a small number of published case reports/families and functional studies (not EHR-derived at scale). Fewer than ~20 unrelated affected individuals/families are described to date.

2. Etiology

Primary cause — genetic. DFNA78 is a monogenic disorder caused by heterozygous, usually dominantly-inherited or de novo, variants in SLC12A2 [human clinical; 32294086; 32658972]. There is no environmental or infectious cause; environmental agents are irrelevant to the primary etiology.

Genetic risk factors. - Causal variants: missense and splice-site variants restricted to exon 21 / its 3′ splice site of the cochlea-specific NKCC1 isoform [PMID 32294086]. ClinVar additionally lists DFNA78-annotated truncating alleles c.2977G>T (p.Glu993Ter) [Pathogenic] and c.869dup (p.Val291fs) [Likely pathogenic] [computational; ClinVar 2026]. - No known common susceptibility loci or modifier genes have been established for DFNA78 (the disorder is monogenic and ultra-rare).

Environmental risk / protective factors. None established as causal or modifying for DFNA78. General SNHL aggravators (noise, ototoxic aminoglycosides, loop diuretics) are theoretical concerns because loop diuretics (bumetanide/furosemide) inhibit NKCC1; avoidance is prudent but not evidence-based for this specific disease.

Gene–environment interactions. Not characterized. Given the ion-transport mechanism, ototoxic drugs that further impair endolymph homeostasis (loop diuretics, aminoglycosides, cisplatin) could plausibly worsen hearing, but no formal GxE data exist.

3. Phenotypes

Core phenotype = bilateral sensorineural hearing loss ± bilateral vestibular areflexia, non-syndromic.

Explicitly NOT part of DFNA78 (these distinguish it from the recessive/de-novo allelic disorders): intellectual disability, developmental delay, gastrointestinal dysmotility, absent salivation/lacrimation, respiratory abnormalities, microcephaly — these occur in Kilquist syndrome (biallelic LoF) and Delpire-McNeill (de novo NDD) [PMID 30740830; 32658972; 33500540].

Quality-of-life impact. SNHL impairs speech/language acquisition, education, and communication; vestibular areflexia impairs balance, gaze stabilization (oscillopsia), and delays motor development. No DFNA78-specific EQ-5D/SF-36 data; QoL burden inferred from congenital bilateral SNHL literature generally.

4. Genetic / Molecular Information

Causal gene. SLC12A2 (Solute carrier family 12 member 2), encoding NKCC1 (Na⁺-K⁺-2Cl⁻ cotransporter 1). HGNC:10911; NCBI Gene 6558; Ensembl ENSG00000064651; UniProt P55011 (1212 aa); locus 5q23.3 (GRCh38 chr5:128,083,766–128,189,677); canonical transcript ENST00000262461 / NM_001046.3 [computational; gnomAD/UniProt].

Pathogenic variants. - Type/class: predominantly missense and splice-site variants in exon 21 / its 3′ splice acceptor (cochlear isoform) [PMID 32294086]; ClinVar also records truncating (nonsense/frameshift) DFNA78 alleles (p.Glu993Ter; p.Val291fs) [ClinVar]. - Classification (ACMG/AMP): the two established DFNA78 alleles are Pathogenic / Likely pathogenic; most other SLC12A2 variants are VUS [ClinVar 2026]. - Allele frequency: private/ultra-rare; absent or singleton in gnomAD (consistent with de novo or small-family dominant transmission). - Origin: germline — inherited (dominant families) or de novo (sporadic cases) [PMID 32294086; 32658972]. No somatic involvement. - Functional consequence: reduced cotransporter activity — "Cl⁻ influx was significantly decreased in all SLC12A2 variants studied" [in vitro Xenopus oocytes; 32294086]. Because NKCC1 is an obligate dimer and heterozygous LoF carriers have normal hearing, DFNA78 missense alleles likely act via dominant-negative / isoform-specific loss of endolymph-secreting function rather than simple haploinsufficiency (partly inferred) [PMID 40503591].

"SLC12A2 functions as a dimer and has several isoforms; only one isoform contains exon 21, and this isoform is almost exclusively expressed in the inner ear/cochlea." — 40503591

Constraint (gnomAD). LOEUF 0.60, LoF o/e 0.49 (obs 67/exp 136), lof_z 5.04, pLI ≈ 0, missense o/e 0.86 (mis_z 2.32) — i.e., SLC12A2 is only moderately LoF-constrained and not classically haploinsufficient, supporting the non-haploinsufficiency mechanism [computational; gnomAD].

Modifier genes / epigenetics / chromosomal abnormalities. None established for DFNA78. (In Kilquist syndrome the causal lesion was a homozygous 22-kb deletion arising via uniparental isodisomy of chromosome 5 — a large-scale mechanism relevant to the recessive allelic disorder, not DFNA78 [PMID 30740830].)

5. Environmental Information

Not applicable to disease causation. No environmental toxins, lifestyle factors, or infectious agents are implicated in DFNA78. Theoretical aggravators of any SNHL — noise exposure, aminoglycosides, cisplatin, and loop diuretics (NKCC1 inhibitors) — should be minimized as general otoprotective practice, but there is no disease-specific evidence.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. A heterozygous SLC12A2 variant in the cochlea-specific exon-21 region (missense/splice/truncating) alters NKCC1 in the exon-21 (inner-ear) isoform [PMID 32294086].
2. The mutant subunit incorporates into the obligate NKCC1 dimer, and (inferred) exerts a dominant-negative / isoform-specific reduction of cotransport in cochlear secretory epithelium — demonstrated as decreased Cl⁻ influx in vitro [PMID 32294086; dimer/mechanism partly inferred, 40503591].
3. Reduced NKCC1 activity in stria vascularis marginal cells (and other lateral-wall cells) decreases basolateral uptake of Na⁺/K⁺/Cl⁻, which results in reduced K⁺ secretion into the endolymph [model organism; 10369265].
4. Impaired K⁺ secretion leads to failure of endolymph homeostasis and reduction of the endocochlear potential (EP) — the driving force for hair-cell transduction currents [PMID 32294086; 17674100].
5. Loss of the K⁺ gradient/EP results in failure of hair-cell mechano-electrical transduction ("K⁺ transport is required for the mechano-transduction of auditory stimuli") [PMID 40503591].
6. Chronic endolymph disturbance leads to structural damage / collapse of the endolymphatic compartment and hair-cell dysfunction (shown in Slc12a2⁻/⁻ mice) [model organism; 10369265].
7. → Sensorineural hearing loss; in parallel, the same defect in vestibular dark cells of the labyrinth results in vestibular hypofunction/areflexia [PMID 32658972].

Molecular pathways / biochemistry. The core defect is an ion-transport (ion-homeostasis) defect, not a classical signaling cascade. NKCC1 mediates electroneutral, bumetanide-sensitive Na⁺:K⁺:2Cl⁻ symport (MF GO:0008511 sodium:potassium:chloride symporter activity). Relevant GO biological processes (UniProt P55011): potassium ion transmembrane transport (GO:0071805), chloride transmembrane transport (GO:1902476), potassium ion import across plasma membrane (GO:1990573), intracellular potassium ion homeostasis (GO:0030007), cell volume homeostasis (GO:0006884), sensory perception of sound (GO:0007605), inner ear morphogenesis (GO:0042472). CHEBI entities: potassium(1+) CHEBI:29103, chloride CHEBI:17996, sodium(1+) CHEBI:29101; inhibitors bumetanide CHEBI:3213, furosemide CHEBI:47426.

Protein dysfunction. NKCC1 is a 12-TM cation-chloride cotransporter that assembles as a homodimer; cryo-EM structures reveal ion-binding sites and the dimer interface [in vitro/structural; 36239040; 32081947; 37545407]. Exon-21 variants perturb the C-terminal cytoplasmic domain critical for transport/regulation; recessive alleles also cluster in the C-terminal domain [PMID 33500540]. Consequence = loss/reduction of transport function (± dominant-negative on the dimer).

Cell types / processes (upstream→downstream). Upstream: dysfunction of strial marginal cells (CL:0002516) and vestibular dark cells (epithelial K⁺ secretion). Downstream: secondary dysfunction/degeneration of cochlear hair cells (inner CL:0000589; outer CL:0000601), vestibular hair cells (CL:0000633), and (later) spiral ganglion neurons (CL:0002253). No inflammation/autoimmunity, apoptosis-driven primary mechanism, or metabolic disorder is implicated in DFNA78.

Molecular profiling. NKCC1 immunolocalizes to the basolateral membrane of strial marginal cells; in hereditary-deaf animal cochleae, spatiotemporal loss of SLC12A2 accompanies strial malformation and endolymph collapse [PMID 18093167; 24713161]. No DFNA78-specific transcriptomic/proteomic/metabolomic datasets exist.

7. Anatomical Structures Affected

• Organ level (primary): inner ear / cochlea (UBERON:0001846 inner ear; UBERON:0001844 cochlea); vestibular apparatus (semicircular canals UBERON:0001840, otolith organs).
• Body systems: special sense (auditory/vestibular) organ of the nervous/sensory system. No cardiovascular, GI, renal, or respiratory involvement in DFNA78 (unlike the multisystem recessive disorder).
• Tissue/cell level: cochlear lateral wall / stria vascularis (UBERON:0002429) secretory epithelium — strial marginal cells (CL:0002516); organ of Corti (UBERON:0002227) — inner/outer hair cells (CL:0000589 / CL:0000601); vestibular dark cells and vestibular hair cells (CL:0000633); endolymph compartment (UBERON:0011078).
• Subcellular level: basolateral plasma membrane (GO:0016323) of secretory epithelial cells (NKCC1 also at apical membrane GO:0016324 in some epithelia); integral membrane transporter.
• Localization / laterality: bilateral (typically symmetric) cochleovestibular involvement.

8. Temporal Development

• Onset: congenital or early-childhood in most reported cases; some heterozygous families show later-onset/progressive SNHL [PMID 32294086; 32658972]. Pattern is chronic/insidious rather than acute.
• Progression: ranges from stable to slowly progressive; severity moderate-to-profound. Vestibular areflexia is generally stable/non-progressive.
• Course/duration: lifelong, non-remitting. No spontaneous remission; no relapsing-remitting pattern.
• Critical period: early identification (newborn hearing screening) and early amplification/cochlear implantation within the first years of life are the key windows for language outcomes.

9. Inheritance and Population

• Inheritance: Autosomal dominant (DFNA78), including de novo occurrences in sporadic cases [PMID 32294086; 32658972].
• Penetrance: appears high in reported dominant families (5/5 affected members in the index family) but formal penetrance estimates are unavailable given few families; treat as likely high but incompletely quantified.
• Expressivity: variable (severity and presence of vestibular involvement differ across individuals).
• Anticipation / germline mosaicism / founder effects: none reported. Founder alleles not described.
• Carrier frequency: not applicable (dominant); SLC12A2 LoF alleles exist in gnomAD but do not cause DFNA78.
• Epidemiology: ultra-rare; exact prevalence/incidence unknown. DFNA (autosomal dominant non-syndromic) deafness collectively is a minority of hereditary hearing loss; DFNA78 is among the rarer subtypes with <20 reported families/individuals. No prevalence per 100,000 can be reliably stated.
• Demographics: reported across multiple populations (Japanese index families [PMID 32294086]; European/other cohorts [PMID 32658972; 40503591]). No sex predilection expected (autosomal). No specific geographic/ethnic clustering established.

10. Diagnostics

Clinical/functional tests. - Audiometry (pure-tone, ABR/auditory brainstem response, OAE, tympanometry): documents bilateral SNHL; OAEs typically absent. LOINC panels for audiometry. - Vestibular testing: video head-impulse test (vHIT), caloric testing, VEMP, rotational chair — reveal vestibular areflexia/hypofunction. - Imaging: MRI/CT of temporal bones — usually normal inner-ear anatomy (helps exclude structural/EVA causes); no pathognomonic finding. - No blood/urine biomarker exists; diagnosis is not made by chemistry.

Genetic testing (diagnostic gold standard). - Recommended approach: hereditary-hearing-loss gene panel or whole-exome sequencing (WES), with attention to SLC12A2 including exon 21 and splice sites (which may be under-covered/mis-annotated because the pathogenic cochlear isoform differs from the canonical transcript) [PMID 32294086]. WES/WGS with trio analysis is especially useful to detect de novo variants [PMID 32658972]. - Single-gene SLC12A2 testing is appropriate when the phenotype (congenital SNHL + vestibular areflexia, dominant/de novo) is suggestive. - CMA/karyotype/FISH generally not indicated (point-variant disorder); mtDNA and repeat-expansion testing not relevant. - Variant-interpretation caveat: confirm variant is in the exon-21 cochlear isoform and, ideally, functional confirmation (reduced Cl⁻/transport) supports pathogenicity [PMID 32294086].

Clinical criteria / differential diagnosis. No formal diagnostic criteria. Differential includes other non-syndromic SNHL genes (GJB2, SLC26A4/Pendred, MYO7A, TMC1, etc.), and syndromic causes with vestibular involvement (Usher syndrome). The combination of non-syndromic congenital SNHL with bilateral vestibular areflexia and dominant/de novo inheritance points toward SLC12A2. Distinguish from the allelic Kilquist (recessive, multisystem) and Delpire-McNeill (NDD) disorders.

Screening. Detected via universal newborn hearing screening (phenotype), then genetic confirmation; cascade testing of at-risk relatives in dominant families.

11. Outcome / Prognosis

• Survival/mortality: DFNA78 is not life-limiting; normal life expectancy. Mortality not attributable to the disease. (Contrast with severe multisystem Kilquist syndrome.)
• Morbidity/disability: principal morbidity is communication disability from bilateral SNHL and balance impairment/oscillopsia from vestibular areflexia; motor milestone delay possible in infancy.
• Disease course: chronic, lifelong; hearing stable-to-progressive.
• Recovery potential: no spontaneous recovery; functional hearing is recoverable with amplification/cochlear implantation, and balance improves with vestibular rehabilitation/compensation.
• Prognostic factors: degree/onset of hearing loss, timing of intervention (early implantation → better language outcomes), and residual hearing. No molecular prognostic biomarker established.
• QoL measures: no DFNA78-specific instruments; general pediatric SNHL QoL tools apply.

12. Treatment

No disease-modifying/curative pharmacotherapy exists. Management is supportive/rehabilitative.

• Amplification / devices: hearing aids for milder loss; cochlear implantation for severe-to-profound loss (NCIT: Cochlear Implant C99286; Hearing Aid C99285). Cochlear implants bypass the failed endolymph-dependent transduction by directly stimulating the auditory nerve and are expected to be effective (spiral ganglion typically preserved early).
• Vestibular rehabilitation / physical therapy for balance; speech-language therapy and early-intervention/educational support.
• Pharmacotherapy: none specific. Note NKCC1 is the target of loop diuretics (bumetanide CHEBI:3213, furosemide) — these inhibit NKCC1 and are potentially ototoxic, so they are not therapeutic and are best avoided. Bumetanide is being studied in NKCC1-related neurodevelopmental/GABA-polarity contexts [PMID 26955005; 38950809], but this is not applicable to restoring cochlear NKCC1 function in DFNA78.
• Advanced/experimental: No approved gene therapy, ASO, or cell therapy for DFNA78. Given the dominant/likely dominant-negative mechanism, allele-selective silencing (siRNA/ASO) or gene editing are conceptually attractive future strategies but remain preclinical/theoretical. No registered clinical trials (ClinicalTrials.gov) target DFNA78 specifically as of this report.
• Pharmacogenomics: avoid concomitant ototoxic drugs (aminoglycosides, cisplatin, loop diuretics).

13. Prevention

• Primary prevention: not possible (genetic). Genetic counseling for dominant families (50% transmission risk); options include prenatal testing and preimplantation genetic testing (PGT) for known familial variants.
• Secondary prevention / early detection: universal newborn hearing screening enables early diagnosis and intervention; cascade genetic testing of relatives.
• Tertiary prevention: early amplification/cochlear implantation and vestibular rehabilitation to prevent language/developmental sequelae; avoidance of ototoxic exposures and noise to preserve residual hearing.
• Immunization / public-health / environmental measures: not applicable.

14. Other Species / Natural Disease

• Taxonomy / orthologs: Slc12a2 is highly conserved. Mouse Slc12a2 (NCBI Gene 20496; MGI:101924; NCBI Taxon 10090); rat Slc12a2 (Taxon 10116); zebrafish slc12a2 (Taxon 7955). Human ortholog UniProt P55011.
• Natural disease in animals: Deafness/inner-ear dysfunction from Slc12a2 disruption is a model-organism phenomenon (targeted mutants); no well-known spontaneous companion-animal DFNA78 equivalent is catalogued (OMIA lists NKCC1/SLC12A2 biology but no established dominant deafness breed disorder).
• Comparative biology: NKCC1's role in endolymph/K⁺ cycling is conserved across mammals (mouse, gerbil, rat, guinea pig) and underlies the shared deafness phenotype [PMID 10369265; 18093167]. Evolutionary conservation of the endolymph-secretion mechanism is strong.
• Transmission: none (non-infectious, non-zoonotic).

15. Model Organisms

• Mouse — Slc12a2 (NKCC1) knockout [model organism; 10369265]: constitutive KO mice are deaf, display classic shaker/waltzer circling/head-bobbing (vestibular dysfunction), and show collapse of the endolymphatic compartment and strial/inner-ear structural damage from reduced endolymph secretion. This recapitulates the core DFNA78 mechanism (endolymph/EP failure) and the cochleovestibular phenotype.

  "absence of functional co-transporter leads to structural damages in the inner ear consistent with a decrease in endol[ymph]" — 10369265

• Allelic mouse models / EP studies: heterozygous Nkcc1 deletion causes progressive, age-dependent hearing loss with EP decline; combined manipulation with Na,K-ATPase isoforms modulates EP and hearing, underscoring NKCC1's role in EP generation [PMID 17674100].
• Other species: guinea-pig hereditary-deafness models show spatiotemporal loss of strial K⁺-transport proteins including SLC12A2 with endolymph collapse [PMID 18093167].
• Model types available: constitutive knockout; heterozygous; the biology also supports conditional/knock-in and humanized approaches (MGI/IMPC resources for Slc12a2).
• Recapitulation & limitations: KO models faithfully reproduce deafness + vestibular dysfunction + endolymph collapse, but represent complete loss of function/biallelic biology (closer to Kilquist) rather than the human heterozygous, isoform-/exon-21-specific dominant mechanism; a precise DFNA78 exon-21 knock-in would better model the dominant-negative disease. No DFNA78 iPSC/organoid model is yet published.
• Databases: MGI (Slc12a2), IMPC/IMSR, Alliance of Genome Resources, ZFIN (slc12a2), RGD.

Supported vs Refuted Hypotheses

Supported: - DFNA78 is caused by heterozygous SLC12A2 variants clustered in the cochlea-specific exon-21 region [PMID 32294086]. - Mechanism = impaired NKCC1-mediated K⁺ secretion → endolymph/EP failure → hair-cell transduction failure → SNHL + vestibular areflexia [PMID 10369265; 32294086; 40503591]. - SLC12A2 is an allelic series (dominant DFNA78 vs recessive Kilquist vs de novo Delpire-McNeill NDD) [PMID 30740830; 32658972; 33500540].

Refuted / disfavored: - Haploinsufficiency as the DFNA78 mechanism — disfavored: gnomAD shows SLC12A2 is not classically haploinsufficient (pLI≈0) and heterozygous LoF carriers/patients have normal hearing; DFNA78 arises from isoform-specific missense/splice (dominant-negative) alleles [PMID 40503591; gnomAD]. - Environmental/infectious causation — not applicable.

Limitations & Future Directions

• Very small number of reported families → penetrance, expressivity, prevalence, natural-history, and audiometric-progression data are limited.
• The dominant-negative mechanism is inferred from the dimeric structure and genotype–phenotype correlation; direct in-vivo proof (exon-21 knock-in models) is lacking.
• No DFNA78-specific omics, iPSC/organoid, or therapeutic-trial data. Future work: exon-21 knock-in mouse, patient iPSC-derived otic organoids, and allele-selective RNA/gene-editing therapeutics.

Key References (PMIDs)

• 32294086 — Mutai et al. 2020: exon-21 SLC12A2 variants cause hereditary hearing loss (foundational DFNA78).
• 32658972 — McNeill et al. 2020: SLC12A2 variants cause NDD or cochleovestibular defect (vestibular areflexia).
• 40503591 — Ludin et al. 2025: de novo SLC12A2 variant, congenital HL + vestibular areflexia; isoform/exon-21 review.
• 30740830 — Macnamara et al. 2019: Kilquist syndrome (biallelic SLC12A2 deletion).
• 33500540 — Bilal Shamsi et al. 2021: autosomal recessive SLC12A2 disease; C-terminal clustering.
• 10369265 — Delpire et al. 1999: Slc12a2-KO mouse deafness/imbalance, endolymph collapse.
• 17674100 — Diaz et al. 2007: NKCC1/Na,K-ATPase, endocochlear potential and hearing.
• 18093167 — Jin et al. 2008: loss of strial K⁺-transport proteins (incl. SLC12A2) in hereditary deafness.
• 36239040 / 32081947 / 37545407 — human NKCC1 cryo-EM structures.
• 33345190 / 37399495 — reviews: NKCC1 as a human disease-causing ion transporter.
• 26955005 / 38950809 — SLC12A2/NKCC1 GABA-polarity and bumetanide (neuro contexts; not DFNA78 therapy).